Whole-exome sequencing and in silico neoantigen prediction have demonstrated that a high level of CD8+ T-cells specific to MUC16 neoantigens is associated with long-term survival in patients with pancreatic cancer. The gene discussed is CD8A; the disease is pancreatic neoplasm.